Anthony Jr. Florence Sells 4,195 Shares of NeueHealth (NYSE:NEUE) Stock

NeueHealth, Inc. (NYSE:NEUE - Get Free Report) Director Anthony Jr. Florence sold 4,195 shares of the stock in a transaction on Thursday, October 2nd. The stock was sold at an average price of $6.75, for a total transaction of $28,316.25. Following the transaction, the director owned 488,702 shares in the company, valued at approximately $3,298,738.50. This trade represents a 0.85% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.NeueHealth Stock PerformanceNeueHealth stock remained flat at $6.75 during mid-day trading on Monday. NeueHealth, Inc. has a twelve month low of $3.79 and a twelve month high of $7.66. The company has a fifty day simple moving average of $6.72 and a two-hundred day simple moving average of $6.72. The firm has a market capitalization of $60.94 million, a PE ratio of -0.42 and a beta of 0.59. NeueHealth (NYSE:NEUE - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The company reported ($1.68) EPS for the quarter, beating analysts' consensus estimates of ($4.77) by $3.09. The company had revenue of $209.08 million for the quarter, compared to analyst estimates of $249.50 million. On average, analysts forecast that NeueHealth, Inc. will post -9.13 earnings per share for the current fiscal year. Institutional Inflows and OutflowsA hedge fund recently bought a new stake in NeueHealth stock. PenderFund Capital Management Ltd. purchased a new stake in NeueHealth, Inc. (NYSE:NEUE - Free Report) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 29,115 shares of the company's stock, valued at approximately $197,000. PenderFund Capital Management Ltd. owned 0.33% of NeueHealth at the end of the most recent reporting period. Hedge funds and other institutional investors own 63.88% of the company's stock. Analyst Upgrades and DowngradesSeparately, Weiss Ratings reiterated a "sell (e+)" rating on shares of NeueHealth in a report on Saturday, September 27th. One analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Reduce" and a consensus price target of $7.00.Get Our Latest Analysis on NEUEAbout NeueHealth (Get Free Report)NeueHealth, Inc, a healthcare company, provides various healthcare services for health consumers, providers, and payors in the United States. It operates through two segments: NeueCare and NeueSolutions. The NeueCare segment delivers healthcare services to ACA marketplace, medicare, and medicaid through owned and affiliated clinics.Featured StoriesFive stocks we like better than NeueHealthWhat is a Low P/E Ratio and What Does it Tell Investors?3 Exceptional Stocks to Build Long-Term WealthRetail Stocks Investing, ExplainedInsider Sales Jump at Broadcom and CoreWeave: Red Flag Ahead?What Do S&P 500 Stocks Tell Investors About the Market? Marvell Insiders Buy Shares—Should Investors Follow Suit?This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.Should You Invest $1,000 in NeueHealth Right Now?Before you consider NeueHealth, you'll want to hear this.MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and NeueHealth wasn't on the list.While NeueHealth currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.View The Five Stocks Here